Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBCUT-HF II: SQIN-Furosemide for Early Supported Discharge in Heart Failure
NCT05419115Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Nov 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SQIN-furosemide in heart failure (HF) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Days Alive Out of Hospital at 30 days. Started Nov 2022; status: completed.
02
Drugs
SQIN-furosemide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05419115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419115.